Skip to content

Spectroscopic Assessment of Tissue Oxygenation Changes During Vascular Surgery

Spectroscopic Assessment of Tissue Oxygenation Changes During Vascular Surgery

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07786623
Enrollment
30
Registered
2026-08-26
Start date
2026-12-01
Completion date
2031-07-31
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Limb-Threatening Ischemia, Ischemia Vascular, Peripheral Arterial Disease, Tissue Ischemia

Keywords

tissue oxygenation, cytochrome c oxidase, near-infrared spectroscopy, intraoperative monitoring, medical device

Brief summary

This study is a single-center, observational study designed to collect tissue spectrometric data related to tissue oxygenation.

Detailed description

A total of 30 participants, aged 18 or older, undergoing planned elective primary vascular surgery will be recruited in this investigation to assess the ability of the SpectroCor Tissue Oxygenation Monitor and its accessory SpectroCor Sensor to monitor peripheral tissue oxygenation perioperatively. The investigation is designed as an open, uncontrolled observational study in which the primary goal is to assess the Monitor's ability, in combination with the Sensor, to monitor tissue oxygenation and safety in routine clinical practice, reflecting the real-world patient population and treatment scenarios. Therefore, no control participants are needed in this investigation.

Interventions

None listed

Sponsors

Spectrocor
Lead SponsorINDUSTRY
Helsinki University Central Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Adults, age of 18 - 90 years * Scheduled for peripheral arterial bypass surgery. * Scheduled for proximal arterial reconstruction. * Ability and willingness to provide informed consent.

Exclusion criteria

* Inability to provide informed consent * Considered a vulnerable person according to the Finnish Medical Research Act (488/1999), Chapter 2, Sections 7, 9, and 10, including retarded persons, pregnant women, nursing mothers, prisoners, and forensic patients. * A known history of severe allergic reaction to nickel.

Design outcomes

Primary

MeasureTime frameDescription
Observe changes in skeletal muscle tissue oxygenationFrom sensor placement prior to arterial clamping until restoration of limb blood circulation and completion of vascular reconstruction quality control (intraoperative period, approximately 2-6 hours)To observe the changes in skeletal muscle tissue oxygenation (combined hemoglobin/myoglobin saturation, %) measured by the SpectroCor Monitoring System during arterial clamping and restoration of limb perfusion. Continuous spectroscopic measurement of combined hemoglobin and myoglobin oxygen saturation in skeletal muscle of the operated limb, recorded from a SpectroCor Sensor placed in the distal wound before any arterial clamping. Saturation values are time-stamped against intraoperative events affecting limb perfusion (proximal arterial clamping, unclamping, graft revision) and compared with paired arterial and venous blood gas samples obtained before clamping and after restoration of blood flow.

Secondary

MeasureTime frameDescription
Incidence of adverse events, adverse device effects, and device deficienciesFrom sensor placement during the operation until discharge from hospital (up to 30 days)Number and proportion of participants experiencing at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE), and the number of device deficiencies (DD) recorded. Events are recorded from the time of sensor placement until discharge from hospital and assessed for causal relationship to the investigational device by the investigator. Anticipated device-related events include topical bleeding at the sensor attachment site, local tissue reaction associated with tissue glue fixation, and local infection at the insertion site.

Contacts

CONTACTTommi Pätilä, PhD
tommi@spectrocor.com+358 440130770
CONTACTKalle Kotilahti
kalle@spectrocor.com+358449016550
PRINCIPAL_INVESTIGATORMaarit Venermo, Professor

Helsinki University Hospital (HUS)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 27, 2026